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ABSTRACT
The prospective study including 166 participants aims to evaluate the association
between seminal prosaposin and the outcomes of in vitro fertilization (IVF) cycles
in humans. The generalized linear model (GLM) was used to analyze the associations
between seminal prosaposin concentrations and normal fertilization rates and good
embryos proportion. The generalized estimating equation (GEE) was used to evaluate
the association between embryo parameters and the prosaposin concentrations. Each
model was adjusted for age of the couples, female basal FSH,AFC andBMI, starting dose
and oocyte yield of IVF cycles and smoker. GLMmodels suggested that prosaposin was
significantly associated with fertilization rate (P = 0.005) and good embryo proportion
(P = 0.038) while none of the semen parameters (sperm concentration, motility,
progressive motility, normal morphology rate, postwash sperm concentration and
motility) was significantly associated with the parameters in the cohort. Using GEE,
it was also shown that prosaposin was positively associated with the occurrence of early
cleavage and negatively associated with uneven cleavage pattern on day 3. In both the
overall population and the normozoospermia patients, the prosaposin was significantly
associated with pregnancy with adjustment with covariates. In conclusion, our data
suggested that seminal prosaposin concentration could provide more information
regarding normal fertilization and embryo development in IVF than traditional semen
parameters.
Subjects Developmental Biology, Andrology, Gynecology and Obstetrics, Women’s Health
Keywords IVF, Seminal plasma, Fertilization, Male infertility, Prosaposin
INTRODUCTION
Semen quality, as measured according to a widely criteria established by World Health
Organization (WHO), is perhaps the most important marker for male infertility potential
in clinical use at the point of time (Sakkas et al., 2015; WHO, 2010). The sperm number
and motility are not only the key determining factors for the ‘‘numbers game’’ to achieve
the necessary tens to hundreds of sperm in the ampulla (Sakkas et al., 2015) but also the
indicators for the health status of male reproductive system itself (Choy & Eisenberg, 2018).
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In the era of ART, in vitro manipulation of gametes allows bypassing of the natural
selection barrier for the spermatozoon in the female reproductive tract, such as hostile
vaginal pH, barrier of cervicalmucus and immune response in the tract, and thus reduces the
importance of the ‘‘numbers game’’ to reach the oocytes (Sakkas et al., 2015). Conflicting
results are obtained from studies regarding the association betweenmale semen quality and
IVF outcomes. A recent study suggested that advancing male age, elevated BMI or poor
sperm quality is not associated with outcomes in frozen donor oocyte IVF cycles (Capelouto
et al., 2018). It suggested that semen quality alone may not yield sufficient information
regarding the potential of male fertility as soon as the spermatozoon reaches the oocytes.
Cumulative studies have investigated and evaluated various additional seminal/sperm
markers beyond traditional seminal quality, among which the abundant tissue-specific
proteins within the seminal plasma provide a rich source of potential candidates (Bieniek,
Drabovich & Lo, 2016; Cao et al., 2018). Proteomic and biomarker discovery technologies
have linked lists of proteins to male infertility etiologies, exposure and life styles (Intasqui et
al., 2015). However, few proteins among the lists has been associated with the functions of
the reproductive process, such as fertilization event and subsequent embryo development.
Prosaposin is known as a lysosomal protein found in Sertoli cells and the lumen of the
seminiferous tubules and epididymis ofmammals (Morales et al., 1998) as well as a secretary
protein identified in the seminal proteome for both men and animals (Codognoto et al.,
2018; Sharma et al., 2013; Viana et al., 2018). In bulls, fertility rank is positively associated
seminal concentration of prosaposin (Viana et al., 2018). In vitro studies showed that the
protein contributes to the sperm-oocyte binding, fertilization and embryo development
in several species (Amann, Hammerstedt & Shabanowitz, 1999a; Amann, Seidel Jr & Brink,
1999b; Amann et al., 1999c; Hammerstedt et al., 2001; Magargee, Cramer & Hammerstedt,
2000). The physiological role of the protein may suggest a functional link between seminal
proteins and reproductive outcomes
IVF cycles may provide an ideal model to observe the association between postulated
markers and events following sperm-oocyte interaction, such as fertilization and embryo
cleavage. The present study aims to evaluate the association between seminal prosaposin
concentration and normal fertilization. Additionally, embryo cleavage patterns during in
vitro culture are used as secondary outcomes.
MATERIALS AND METHODS
Institutional review board approval for this study was obtained from the Ethical Committee
of Medical College Xiamen University. All the subjects enrolled in this study were given
written formal consent before participation. No clinical trial registry was necessary because
the study did not involve any type of intervention.
Participants
Participants were recruited between Jan 2013 and June 2016. Tominimize the confounding
from female participants, we included only patients receiving conventional IVF treatment
for the first time, undergoing conventional long agonist for ovarian stimulation. Female
participants were with good physical and mental health, aged <35 years; regular menstrual
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cycles ranging from 25 to 35 days; BMI < 28 kg/m2; normal basal serum FSH (≤10
mIU/ml) and estradiol (E2) (≤75 pg/ml). No sign of male reproductive tract infection was
detected in the male participants. The exclusion criteria were: patients with endometriosis
or PCOS, patients with suboptimal ovarian response (oocyte yield <5) and patients with
sign of OHSS.
Ovarian stimulation
All patients received the same regimen using depot GnRH agonist (Ren et al., 2014).
Patients received 2–3 ampoules (150–225 IU) gonadotrophin per day during the
gonadotrophin stimulation. The starting dose was adjusted according to patients‘ age, AFC
and BMI. Physicians triggered oocyte maturation using 5000–10000 IU human chorionic
gonadotrophin (hCG; Lizhu Pharma, China) as soon as ultrasonography revealed at least
one follicle measuring≥18 mm in mean diameter. Oocyte retrieval was scheduled 34 to 36
hr after triggering.
Semen preparation
Semen parameters of male counterparts were evaluated according to WHO criteria.
On the day of oocyte retrieval, semen was produced by masturbation and motile
spermatozoa were prepared by centrifugal fractionation (350G, 10 min) using sperm
isolation medium (Isolate, Irvine Scientific, CA). Resulting spermatozoa was washed
(250G, 5min) in gamete buffer (K-SIGB-50, Cook, Australia) and incubated in 37 ◦C until
insemination.
Semen samples (100 µl) for prosaposin determination were collected before centrifugal
fractionation. The spermatozoa were removed following high speed centrifugation
(14000G, 10min). The seminal plasma was stored at −80 ◦C until use.
Embryo culture and assessment
Oocytes were inseminated 4 hr after collection. Pronuclei (PN) were identified 18 hr later.
All embryos were cultured in traditional incubators (C200, Labotech, Germany) at 37 ◦C,
6%CO2, 5%O2. Occurrence of early cleavage event was observed at 27 hr post insemination.
Day 3 embryos were graded based on numbers of embryo blastomere, fragmentation, and
symmetry. Grade 1 and grade 2 embryos were considered as high quality embryos, grade
1, grade 2, and grade 3 embryos were considered as available embryos. Embryo transfer
procedure and pregnancy determinant were described in our previous research.
Determination of prosaposin
Prosaposin was determined using an ELISA kit (Uscn Life Science Inc., Wuhan, China)
according to the manufacturer’s instructions. All samples were thawed and diluted five
folds in PBS. The color change of the substrate is measured spectrophotometrically at a
wavelength of 450 nm. The concentration of prosaposin in the samples is then determined
by comparing the O.D. of the samples to the standard curve. The lower detection limit of
the analysis is less than 8.2 pg/ml.
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Statistical analysis
The primary outcome of the study was normal fertilization rate. Normal fertilization
rate rather than total fertilization rate was used because it is a key performance indicator
for IVF procedure (ESHRE Special Interest Group of Embryology and Alpha Scientists in
Reproductive Medicine, 2017) and ismore relevant to the outcome. The secondary outcomes
were the parameters associated with embryo development following fertilization, including
good embryo proportion, occurrence of early event on day 1, fragmentation, cleavage speed
and cleavage pattern on day 3. Normal fertilization rate was defined as the proportion of
2PN or 2PB of cumulus-oocyte complexes inseminated (ESHRE Special Interest Group of
Embryology and Alpha Scientists in Reproductive Medicine, 2017). Good embryo proportion
was the proportion of good embryos among normally fertilized oocytes.
Generalized linear model was used to evaluate the association between prosaposin
concentration and good embryos proportion. The model was adjusted for age of the
couples, female basal FSH, AFC and BMI, starting dose and oocyte yield of IVF cycles and
male smoker.
Generalized estimating equation was used to analyze the association between prosaposin
concentrations and embryo parameters (fragmentation >10%, early cleavage, fast cleavage,
slow cleavage, on time cleavage, unsynchronized cleavage and uneven cleavage). Embryos
from the same cycle were treated as dependent samples in the analysis.
Traditional semen parameters (sperm concentration, motility, progressive motility,
normal morphology rate, postwash sperm concentration and motility) were also associated
with the outcomes in the same manner.
Multivariate model was also used to detect the association between prosaposin
and pregnancy. Beside the covariate aforementioned, the model was also adjusted for
endometrial thickness, stage of embryo transferred (cleavage vs blastocyst), number of
embryos transferred and distance from transfer catheter tip to fundal.
Correlation between prosaposin concentrations and semen parameters were calculated
according to spearmen correlation coefficient.
Data analysis was performed using SPSS Version 19.0 statistical software (IBM, Armonk,
NY).
RESULTS
A total of 166 couples were involved in the study. As demonstrated in Table 1,
female counterparts were normal responders with a median oocyte yield of 11.
The median age of the female patient was 31 years. None of the selected patients
was with endometriosis, PCOS or other diagnosed endocrine dysfunction. Among
male counterparts, the median age was 32 years. More than half of them (n= 87,
52.4%) were with normozoospermia according to WHO criteria. Others were with
asthenozoospermia (n = 54), teratozoospermia (n = 12), asthenoteratozoospermia
(n= 9), oligoasthenozoospermia (n= 2), oligoasthenoteratozoospermia (n= 1) or
oligozoospermia(n= 1). The median prosaposin concentration in the seminal plasma
was 73.12 ng/ml. The prosaposin concentration significantly correlated with progressive
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Table 1 Patient characteristics and cycle parameters.
n 166
Female characteristics
Female age, year 31[5]
BMI, kg/m2 21.3[3.23]
Basal FSH, mIU/ml 6.66[2.17]
Basal LH, mIU/ml 4.03[2.12]
Basal E2, pg/ml 35[25.25]
AFC 12[7]
Male characteristics
Male age, year 32[6.25]
BMI, kg/m2 23.51[4.36]
Smoker (%) 94(56.6)
Prosaposin, ng/ml 73.12[95.52]
Semen volume, ml 2.5[1]
FSH, mIU/ml 5.15[1.91]
Sperm concentration,×106/ml 59.69[56.2]
Total sperm count,×106 149.96[154.16]
Normal morphology, % 6.5[6]
Motility, % 50.35[22.37]
Total motile sperm,×106 68.96[84.13]
Progressive, % 36.74[18]
Non progressive, % 9[7.02]
Immotile, % 49.15[22.06]
Postwash sperm concentration,×106/ml 40[15]
Postwash sperm motility, % 98[3]
Postwash progressive motility, % 95[5]
Postwash nonprogressive motility, % 3[2]
Cycle parameters
Gonadotropin dose, IU 2475[740.63]
Duration of stimulation, day 12[3]
Starting dose, IU 225[75]
Oocyte yield 11[4]
Endometrial thickness, mm 10.9[3.45]
Fertilization rate, % 87.87[22.22]
Normal fertilization rate,% 70[22.86]
Normal fertilization <50% (%) 29 (17.5)
Good embryo proportion,% 63.07[35.12]
ET cancelled (%) 7 (4.2)
Cleavage ET (%) 111 (69.8)
Blastocyst ET (%) 48 (30.2)
Number of embryos transferred 2 [1]
Pregnancy/ET (%) 103/159 (64.78)
Notes.
ET, embryo transfer.
Data are median [IQR] or count (percentage).
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motility and postwash sperm motility but not sperm concentration or morphology
(Table 2).
In multivariate analyses, the concentrations of seminal prosaposin were positively
associated with normal fertilization rate (P < 0.01). The regression coefficient indicated
that per ng/ml increase in seminal prosaposin would lead to 0.066% increase in normal
fertilization rate after adjustment of confounding factors. On the other hand, however, none
of the traditional semen parameters, such as sperm concentration, motility and normal
morphology rate was significantly associated with normal fertilization rate (Table 3). To
test the robustness of the association, we carried out a sensitivity analysis in a subgroup
of patients with normozoospermia (n= 87). Although the P value (0.042) was increased
due to the small sample size, the result was consistent with that in the total population
(Table 3).
To compare the ability of seminal prosaposin and standard semen parameters in
predicting low fertilization events (normal fertilization rate <50%), receiver operating
characteristic (ROC) curves was used to determine which cutoff would provide the best
trade-off between sensitivity and specificity and AUC for each predictors were qualified
(Table 4). It is shown that in both the overall population and the normozoospermia
men, prosaposin showed limited discriminating capacity to predict the cycles with low
fertilization, where either the sperm concentration nor the sperm motility showed any
discriminating capacity (AUC<0.6, P > 0.05).
In Table 5, we further associated individual embryo parameter with prosaposin using
GEE and found that prosaposin concentration was significantly associated with the
occurrence of early cleavage on day 1 and uneven cleavage pattern on day3 (Table 5). On
the other hand, the sperm motility was significantly associated with early cleavage and
postwash sperm motility was negatively associated with fast cleaving of day 3 embryos.
We also explored the association between seminal prosaposin and pregnancy following
embryo transfer (Table 6).With adjustment of semen volume, the prosaposin concentration
was significantly associated with pregnancy. In univariate model, however, prosaposin was
not significantly associated with pregnancy in either overall population (OR 1.004, 95%CI
[0.998–1.004]) or Normozoospermic men (OR 1.006, 95%CI [0.998–1.014]).
DISCUSSION
Although the detail is not clear, the role of prosaposin in male fertilization and
spermatozoa-oocyte interaction has been revealed in several species (Amann, Hammerstedt
& Shabanowitz, 1999a; Amann, Seidel Jr & Brink, 1999b; Amann et al., 1999c; Hammerstedt
et al., 2001; Magargee, Cramer & Hammerstedt, 2000). Conservation of evolution may
suggest the importance of the protein in male reproductive process. However, it is still not
known whether there is any clinical importance of this protein among patients receiving
infertility treatment. The present study is adding to existing knowledge by demonstrating
the role of seminal prosaposin in predicting the fertilization, embryo development and
pregnancy in patients receiving IVF. The data suggested that prosaposin concentration in
semennot only hadmoderate predicting value in low fertilization event but also significantly
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Table 2 Correlation between prosaposin concentration and semen parameters.
Correlation coefficient P
Sperm concentration 0.13 0.096
Normal morphology −0.153 0.051
Motility −0.01 0.893
Progressive motility 0.197 0.011
Postwash sperm concentration −0.115 0.141
Postwash sperm motility 0.269 <0.001
Postwash progressive motility 0.266 0.001
FSH levels 0.098 0.21
correlated to embryo development and pregnancy following fertilization. Because seminal
plasma is removed during preparation of spermatozoon in IVF procedures, the prosaposin
in seminal plasma may not be directly involved in the sperm-oocyte interaction. It is
possible that the concentration of prosaposin reflects the health status of reproductive
system. As shown in our previous study, the prosaposin associated with spermatozoon may
reflect the external exposure and internal body burden of environmental pollutants (Cai
et al., 2015). The finding also echoes a recent proteomics study in which seminal proteins
such as prosaposin may indicate the fertility ranking of the males in bulls (Viana et al.,
2018).
A number of research groups have associated seminal plasma protein levels with semen
parameters (Cao et al., 2018; Davalieva et al., 2012; Diamandis et al., 1999; Drabovich et
al., 2013; Freour et al., 2013; Rolland et al., 2013; Wang et al., 2009). Panels of candidate
proteins for male fertility have been proposed in studies comparing the proteomics data
between normozoospermic men and men with asthenozoospermia, oligozoospermia, or
azoospermia. The semen parameters, however, may only have limited predicting value
for clinic outcomes among IVF patients. Bartolacci et al. suggested that oligozoospermia
according to WHO criteria may affect the embryo development but not top quality
blastocyst formation rate or the establishment of pregnancy in ICSI cycles (Bartolacci et
al., 2018). In a study including 1280 IVF cycles, Mariappen et al. suggested that the semen
parameters have an insignificant role to play in embryo quality and overall outcomes
(Mariappen et al., 2018). Similarly, Capelouto et al. found a lack of association between
semen parameters and live birth rate in frozen donor oocyte cycles (Capelouto et al., 2018).
These studies may lie on the fact that several critical processes of natural conception
are bypassed by the ART treatment and suggest that male fertility biomarkers screened
according to semen parameters may not be as feasible as they were expected in ART
populations. In the present study, the association between seminal protein and outcomes of
IVF treatmentwas not only observed in the overall population but also in normozoospermic
men. On the other hand, neither sperm concentration nor sperm motility was significantly
associated with normal fertilization and pregnancy. The data supported the hypothesis that
seminal proteins provide more information regarding fertility than routine semen analysis
and suggested that male factor might still affect the reproductive outcome even though the
semen parameters are considered as normal according to the established criteria.
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Table 3 Multivariate analysis for normal fertilization rate and good embryo proportion, with respect
to prosaposin concentration and semen quality. Each model was adjusted for age of the couple, female
BMI, female basal FSH, AFC, starting dose, oocyte yield and male smoker.
Normal fertilization Good embryo proportion
Coefficient P Coefficient P
Overall population, n= 166
Prosaposin 0.066 0.005 0.070 0.038
Sperm concentration 0.046 0.118 −0.040 0.342
Male FSH 0.169 0.801 −1.984 0.033
Normal morphology 0.115 0.685 0.100 0.800
Motility 0.007 0.934 −0.203 0.422
Progressive motility 0.067 0.499 0.067 0.632
Postwash sperm concentration −0.071 0.554 −0.273 0.101
Postwash motility 0.005 0.979 −0.234 0.358
Postwash progressive motility 0.077 0.664 −0.210 0.399
Normozoospermia, n= 87
Prosaposin 0.066 0.042 0.049 0.325
Sperm concentration 0.045 0.330 0.006 0.925
Male FSH −0.248 0.781 −2.3 0.066
Normal morphology 0.233 0.577 0.314 0.595
Motility −0.038 0.837 −0.059 0.819
Progressive motility 0.026 0.921 0.244 0.511
Postwash sperm concentration 0.194 0.296 −0.479 0.066
Postwash motility 0.855 0.586 4.681 0.032
Postwash progressive motility 0.843 0.361 1.940 0.135
Our data also provide a detailed look at the association male factor and embryo
development by linking the individual embryo morphological parameters with semen
parameters and seminal protein using GEE. As shown in Table 5, male factors have been
associated with cleavage events at early development, such as early cleavage on day 1 and
cleavage rates on day 3. Occurrence of early cleavage at a given time point is deemed as
a significant predictor for embryo implantation (Alpha Scientists in Reproductive Medicine
and ESHRE Special Interest Group of Embryology, 2011). The use of modern time lapse
technology further confirmed the importance of the timing and period of early cleavages
before genomic activation in predicting embryo developmental competence (Kaser et al.,
2017). Under experimental condition, it is shown that the 2nd to 3rd mitoses were sensitive
periods in the presence of spermatozoal oxidative stress (Burruel et al., 2014). It could also
be postulated that early cleavage events of embryos were also sensitive to spermatozoal
oxidative stress derived from physiological or pathological conditions.
Due to the complexity of reproductive process, it is difficult to associate a single semen
maker with pregnancy outcome. Conflicting evidence regarding the association between
male factors and ART outcomes was not only observed in studied using semen parameters
as male fertility markers (Bartolacci et al., 2018; Borges Jr et al., 2016; Capelouto et al., 2018;
Chapuis et al., 2017; Mariappen et al., 2018; Mazzilli et al., 2017), but also in those using
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Table 4 Discriminating capacity of prosaposin concentration and semen quality for low fertilization
(normal fertilization< 50%) in ROC curves.
Cutoff Sensitivity Specificity AUC (95%CI) P
Overall population, n= 166
Prosaposin 63.35 0.76 0.60 0.666(0.569–0.763) 0.006
Sperm concentration 48.63 0.55 0.67 0.582(0.46–0.705) 0.171
FSH 3.39 0.86 0.21 0.474(0.362–0.585) 0.655
Normal morphology 17.40 1.00 0.07 0.433(0.325–0.541) 0.266
Motility 63.53 0.93 0.15 0.511(0.389–0.632) 0.861
Progressive motility 36.74 0.59 0.53 0.548(0.426–0.67) 0.429
Postwash sperm concentration 52.50 0.90 0.19 0.529(0.419–0.638) 0.632
Postwash motility 96.50 0.48 0.72 0.604(0.483–0.725) 0.085
Postwash progressive motility 91.00 0.48 0.69 0.602(0.485–0.719) 0.089
Normozoospermia, n= 87
Prosaposin 63.35 0.88 0.62 0.707(0.592–0.822) 0.010
Sperm concentration 48.63 0.50 0.77 0.61(0.456–0.764) 0.171
FSH 8.81 0.063 0.972 0.436(0.284–0.588) 0.436
Normal morphology 11.75 0.88 0.25 0.437(0.294–0.581) 0.437
Motility 63.53 0.88 0.21 0.412(0.248–0.576) 0.276
Progressive motility 36.74 0.25 0.87 0.516(0.346–0.686) 0.844
Postwash sperm concentration 31.50 0.38 0.86 0.614(0.446–0.781) 0.158
Postwash motility 96.00 0.38 0.82 0.547(0.372–0.722) 0.558
Postwash progressive motility 91.00 0.38 0.79 0.573(0.414–0.732) 0.363
othermale fertility biomarkers, such as DNA fragmentation (Colaco & Sakkas, 2018).While
many of the previous analyses were univariate in nature, the conflicting results may imply
the importance of adjustment for the confounding factors associated with maternal factors.
During the reproductive process, the female contribute to not only the maternal genetic
material but also most of the cell machinery of the zygote and the environment for embryo
implantation and fetal growth. In predicting the outcomes of IVF, maternal factors such
as gynecological etiologies, ovarian response, maternal age and endometrial thickness may
play significant roles (McLernon et al., 2016). In their study investigating the effects of male
factor on ART outcomes, Mariappen et al. found that female age but not male age or semen
parameters has significant influence on pregnancy or live birth (Mariappen et al., 2018).
In our study, the association between male fertility and IVF outcomes is strengthened by
a prospective cohort in which female counterparts with good prognosis were selected and
important covariates for IVF outcomes were considered.
CONCLUSIONS
In conclusion, the present study demonstrated the association between prosaposin, a
seminal secretory protein and the occurrence of fertilization and embryo cleavage events.
Our data also suggested that seminal proteins may provide more information regarding
IVF outcomes than traditional semen parameter could yield. Although the AUC suggest
only a limited discriminating capacity of prosaposin to predict low fertilization events, a
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Table 5 Association between embryo parameters and prosaposin concentration/semen quality. Each model was adjusted for age of the couple, female BMI, basal FSH,
AFC, starting dose, oocyte yield and male smoker. Fast cleaving embryo was defined as an embryo with more than eight cells at the time of observation; slow cleaving em-
bryo was defined as an embryo with less than eight cells at the time of observation; Nonsynchronized cleaving embryo was defined as an embryo with even cell number at
the time of observation.
Early cleavage on day 1 Fast cleaving embryo
on day3
Slow cleaving embryo
on day3
On time 8 cell
embryo on day3
Unsynchronized cleaving
embryo on day3
Fragmentation>10%
on day3
Uneven cleaving
embryo on day3
Overall population, n= 1252
Prosaposin 1.005(1.002–1.009)** 1.002(0.999–1.005) 0.999(0.996–1.002) 0.999(0.997–1.002) 1.001(0.999–1.003) 0.997(0.993–1.001) 0.997(0.995–0.999)*
Sperm concentration 1.001(0.997–1.005) 0.998(0.994–1.002) 1.002(0.997–1.006) 1.001(0.997–1.003) 1.001(0.998–1.002) 1.001(0.995–1.004) 1.001(0.998–1.004)
Male FSH 0.962(0.89–1.04) 1.051(0.98–1.128) 0.99(0.94–1.045) 0.969(0.93–1.014) 0.978(0.93–1.024) 1.043(0.96–1.137) 1.07(1.01–1.139)*
Normal morphology 0.994(0.952–1.038) 0.995(0.963–1.029) 0.992(0.966–1.018) 1.015(0.993–1.037) 0.997(0.977–1.017) 0.981(0.933–1.033) 0.984(0.952–1.016)
Motility 0.999(0.986–1.011) 0.998(0.979–1.017) 0.994(0.98–1.008) 1.002(0.989–1.016) 0.999(0.992–1.006) 0.96(0.876–1.053) 1.011(0.996–1.025)
Progressive motility 1.020(1.005-1.036)** 0.992(0.981–1.003) 1.001(0.988–1.012) 1.002(0.992–1.012) 1.003(0.993–1.013) 1.012(0.994–1.030) 1.003(0.992–1.014)
Postwash sperm concentration 0.997(0.982–1.013) 1.001(0.987–1.014) 1.003(0.992–1.014) 0.996(0.986–1.006) 1.007(0.999–1.016) 1.015(0.953–1.081) 1.003(0.986–1.021)
Postwash motility 1.087(0.960–1.232) 0.982(0.974–0.991) ** 1.007(0.999–1.015) 1.012(0.994–1.030) 1.005(0.998–1.013) 1.016(0.954–1.081) 1.020(0.984–1.058)
Postwash progressive motility 1.028(0.983–1.076) 0.980(0.968–0.991)** 1.010(0.999–1.020) 1.010(0.994–1.026) 1.003(0.993–1.014) 1.017(0.955–1.082) 1.008(0.984–1.033)
Normozoospermia, n= 645
Prosaposin 1.003(0.999–1.007) 1.004(1.001–1.007)** 0.996(0.993–0.999)* 1.001(0.998–1.002) 1.001(0.998–1.003) 0.997(0.991–1.003) 1.001(0.997–1.003)
Sperm concentration 1.003(0.998–1.008) 1(0.996–1.005) 0.999(0.995–1.003) 1.002(0.999–1.006) 0.998(0.994–1.002) 0.996(0.987–1.005) 0.998(0.992–1.003)
Male FSH 0.936(0.88–0.996)* 0.96(0.89–1.039) 1.061(1–1.127) 0.964(0.92–1.009) 0.996(0.95–1.05) 1.077(0.94–1.23) 1(0.94–1.059)
Normal morphology 0.998(0.933–1.067) 1.024(0.974–1.076) 0.99(0.948–1.034) 1.003(0.974–1.033) 1.019(0.99–1.049) 0.939(0.88–1.001) 0.999(0.969–1.03)
Motility 0.995(0.974–1.017) 1.009(0.991–1.028) 0.987(0.968–1.006) 1.007(0.993–1.022) 0.987(0.969–1.004) 0.98(0.945–1.017) 0.985(0.966–1.004)
Progressive motility 1.019(0.991–1.048) 0.992(0.968–1.017) 0.983(0.959–1.006) 1.021(1.003–1.039)* 0.995(0.973–1.017) 1.003(0.963–1.045) 0.991(0.966–1.018)
Postwash sperm concentration 1.003(0.982–1.025) 1.001(0.98–1.022) 1.019(0.998–1.04) 0.984(0.97–0.998)* 1.016(1.00–1.033)* 1.031(0.997–1.066) 1.004(0.98–1.029)
Postwash motility 1.017(0.811–1.275) 1.022(0.847–1.234) 0.935(0.793–1.101) 1.062(0.924–1.22) 0.943(0.831–1.07) 0.896(0.696–1.155) 0.978(0.831–1.152)
Postwash progressive motility 0.968(0.846–1.107) 0.985(0.883–1.099) 1.011(0.914–1.119) 1.011(0.934–1.093) 0.977(0.906–1.053) 0.949(0.82–1.098) 0.966(0.878–1.064)
Notes.
*Indicates significant at P < 0.05.
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Table 6 Multivariate analysis forclinical pregnancy (n= 157).
Variable Category OR (95% CI)
Overall Normozoospermia
Female age per year increased 0.973(0.834–1.135) 0.905(0.704–1.162)
Male age per year increased 1.028(0.899–1.175) 1.095(0.885–1.355)
Female BMI per unit increased 0.982(0.859–1.122) 0.917(0.768–1.094)
Female basal FSH per mIU/ml increased 0.985(0.802–1.211) 1.559(0.992–2.451)
Male FSH per mIU/ml increased 1.06(0.877–1.281) 1.041(0.718–1.507)
AFC per AFC increased 1.008(0.923–1.101) 1.067(0.933–1.219)
Male smoker no smoker vs smoker 0.468(0.206–1.063) 0.597(0.158–2.249)
Prosaposin concentration per ng/ml increased 1.009(1.001–1.016)* 1.018(1.004–1.032)*
Semen volume per ml increased 1.687(1.059–2.687)* 3.3(1.448–7.52)*
Sperm concentration per 106/ml increased 0.994(0.986–1.003) 0.991(0.976–1.006)
Normal morphology per percentage increased 1.019(0.935–1.11) 1.258(1.048–1.511)*
Motility per percentage increased 1.007(0.984–1.031) 1.029(0.973–1.087)
Starting dose per IU increased 1.002(0.991–1.015) 1.01(0.991–1.029)
Oocyte yield per oocyte increased 1.094(0.956–1.252) 1.121(0.881–1.426)
Distance to fundal per cm increased 0.953(0.308–2.953) 0.303(0.046–1.985)
Number of embryo transferred per embryo increased 0.697(0.219–2.219) 4.761(0.452–50.106)
Endometrial thickness per mm increased 1.244(1.036–1.493)* 1.221(0.932–1.6)
At least on top quality embryo transferred yes vs no 5.541(1.436–21.381)* 35.2(2.846–435.317)*
Stage of embryo transfer cleavage vs blastocyst 1.158(0.334–4.021) 8.031(0.704–91.582)
Notes.
*Indicates significant at P < 0.05.
panel of seminal proteomics markers may provide a higher discriminating capacity in the
future.
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